Repeated co-treatment with imipramine and amantadine induces hippocampal brain-derived neurotrophic factor gene expression in rats

Journal of Physiology and Pharmacology

Volumn 58, Issue 2, 2007, Pages 219-234

  Rogóz, Zofia ^a   Skuza, G ^a   Legutko, B ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

5 HT1A and 5 HT2A syndrome; Amantadine; Imipramine; mRNA BDNF; Rats; Repeated treatment

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; AMANTADINE; BRAIN DERIVED NEUROTROPHIC FACTOR; IMIPRAMINE; MESSENGER RNA; SEROTONIN 1A AGONIST; SEROTONIN 2A AGONIST;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; BRAIN CORTEX; CONTROLLED STUDY; DEPRESSION; DISSECTION; DRUG EFFECT; DRUG POTENCY; ENHANCER REGION; GENE EXPRESSION; HIPPOCAMPUS; MALE; NONHUMAN; NORTHERN BLOTTING; RAT; WISTAR RAT;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; AMANTADINE; AMPHETAMINES; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION; HIPPOCAMPUS; IMIPRAMINE; MALE; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, MESSENGER; SEROTONIN;

EID: 34347397365     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Trullas R, Skolnik P. Functional antagonists of the NMDA receptor complex exhibit antidepressant action. Eur J Pharmacol 1990; 185: 1-10.
2. Maj J, Rogóż Z, Skuza G, Sowińska H. The effect of CGP 37849 and CGP 39551, competitive NMDA receptor antagonist, in the forced swimming test. Pol J Pharmacol 1992; 44: 337-346.
3. Moryl E, Danysz W, Quack G. Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol 1993; 72: 394-397.
4. Papp M, Moryl E. Antidepressant activity of uncompetitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur J Pharmacol 1994; 263: 1-7.
5. Rogóż Z, Skuza G, Maj J, Danysz W. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology 2002; 42: 1024-1030.
6. Skuza G, Rogóż Z. The synergistic effect of selective sigma receptor agonists and uncompetitive NMDA receptor antagonists in the forced swim test in rats. J Physiol Pharmacol 2006; 57: 217-229.
7. Rogóż Z, Skuza G, Kuśmider M, Wójcikowski J, Kot M, Daniel WA. Synergistic effect of imipramine and amantadine in the forced swimming test in rats. Behavioral and pharmacokinetic studies. Pol J Pharmacol 2004; 56: 179-185.
8. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351-354.
9. Rogóż Z, Dziedzicka-Wasylewska M, Daniel WA, et al. Effects of joint administration of imipramine and amantadine in patients with drug-resistant unipolar depression. Pol J Pharmacol 2004; 56: 735-742.
10. Stryjer R, Strous RD, Shaked G, et al. Amantadine as augmentation therapy in the management of treatment-resistant depression. Int Clin Psychopharmacol 2003; 18: 93-96.
11. Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 1997; 12 (suppl 3): S7-S14.
12. Skolnik P. Antidepressants for the new millennium. Eur J Pharmacol 1999; 375: 31-40.
13. D'Aquila PS, Collu M, Gessa GL, Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 2000; 405: 365-373.
14. Vetulani J, Nalepa I. Antidepressants: past, present, and future. Eur J Pharmacol 2000; 405: 351-363.
15. Millan MJ. The role of monoamines in the action of established and "novel" antidepressant agents: a critical review. Eur J Pharmacol 2004; 500: 371-384.
16. Rogóż Z, Budziszewska B, Kubera M, et al. Effects of combined treatment with imipramine and metyrapone on the immobility time, the activity of hypothalamo-pituitary-adrenocortical axis and immunological parameters in the forced swimming test in the rat. J Physiol Pharmacol 2005; 56: 49-61.
17. Chen B, Dowlatshahi D, MacQueen GM, Wong J-F, Young LT. Increased hippocampal BDNF immunoreactivity in subject treated with antidepressant medication. Biol Psychiatry 2001; 50; 260-265.
18. Shimizu E, Hashimoto K, Okamura N, et al. Alternations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003; 54: 70-75.
19. Aydemmir O, Deveci A, Taneli F. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog Neuro-Psychopharmacol Biol Psychiatry 2005; 29: 261-265.
20. Gervasoni N, Aubry JM, Bondolfi G, et al. Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology 2005;51:234-238.
21. Gonul AS, Akdeniz F, Taneli F, Donat O, Eker C, Vahip S. Effect of treatment on serum brain-derived neurotrophic factor level in depressed patients. Eur Arch Psychiatry Clin Neurosci 2005; 255: 381-386.
22. Aydemmir C, Yalcin ES, Aksaray S, et al. Brain-derived neurotrophic factor (BDNF) changes in the serum of depressed women. Prog Neuro-Psychopharmacol Biol Psychiatry 2006; 30: 1256-1260.
23. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15: 7539-7547.
24. Russo-Neustadt A, Beard RC, Cotman CW. Exercise, antidepressant medications, and enhanced brain-derived neurotrophic factor expression. Neuropsychopharmacology 1999; 21: 679-682.
25. Coppell AL, Pei Q, Zetterstrom TSC. Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology 2003; 44: 903-910.
26. Dias BG, Banerjee SB, Duman RS, Vajdya VA. Differential regulation of brain-derived neurotrophic factor transcripts by antidepressant treatments in the adult rats brain. Neuropharmacology 2003; 45: 553-563.
27. De Foubert G, Carney SL, Robinson CS, et al. Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience 2004; 128: 597-604.
28. Russo-Neustadt AA, Alejandre H, Garcia C, Ivy AS, Chen MJ. Hippocampal brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise. Neuropsychopharmacology 2004; 29: 2189-2199.
29. Jacobsen JPR, Mørk A. The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels. Brain Res 2004; 1024: 183-192.
30. Russo-Neustadt AA, Chen MJ. Brain-derived neurotrophic factor and antidepressant activity. Curr Pharm Des 2005; 11: 1495-1510.
31. Rogóż Z, Skuza G, Legutko B. Repeated treatment with mirtazapine induces brain-derived neurotrophic factor gene expression in rats. J Physiol Pharmacol 2005; 56: 661-671.
32. Rogóż Z, Legutko B. Combined treatment with imipramine and metyrapone induces hippocampal and cortical brain-derived neurotrophic factor gene expression in rats. Pharmacol Rep 2005; 57: 840-844.
33. Legutko B, Li X, Skolnik P. Regulation of BDNF expression in primary neuron culture by LY392098, a novel AMPA receptor potentiator. Neuropharmacology 2001; 40: 1019-1027.
34. 1 receptor and of the catecholaminergic system in the behavioral response to 8-hydroxy-29di-n-propylamino0tetralin in the rat. Eur J Pharmacol 1985; 106: 272-282.
35. Morvanova M, Lakso M, Pirhonen J, Nawa H, Wong G, Castren E. The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Mol Cell Neurosci 2001; 18: 247-258.
36. Linden AM, Vaisanen J, Lakso M, Nawa H, Wong G, Castren E. Expression of neurotrophic BDNF and NT-3, and their receptors in rat brain after administration of antipsychotic and psychotic agents. J Mol Neurosci 2000; 14: 27-37.
37. Matsuki H, Shirayama Y, Hashimoto K, Tanaka A, Minabe Y. Effect of age and gender on the expression of brain-derived neurotrophic factor mRNA in rat retrosplenial cortex following administration of dizocilpine. Neuropsychopharmacology 2001; 25: 258-266.
38. Toyomoto M, Inoue S, Ohta K, et al. Production of NGF BDNF and GDNF in mouse astrocyte cultures is strongly enhanced by a cerebral vasodilator, ifenprodil. Neurosci Lett 2005: 379: 185-189.
39. Mattson MP, Maudsley S, Martin B. BDNF and 5-HT a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci 2004; 27: 589-594.
40. Maj J, Bijak M, Dziedzicka- Wasylewska M, Rogóż Z, Skuza G, Tokarski K. The effect of paroxetine given repeatedly on the 5-HT receptor subpopulations in the rat brain. Psychopharmacology 1996; 127: 73-82.
41. Maj J, Moryl E. Effect of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations. J Neural Transm [Gen Sect] 1992; 88: 143-156.
42. Maj J, Moryl E. Effect of fluoxetine given chronically on the responsiveness of 5-HT receptor subpopulations to their agonists. Eur Neuropsychopharmacol 1993; 3: 85-94.
43. Owen JCE, Whitton PS. Effect of amantadine and budipine on antidepressant drug-evoked changes in extracellular 5-HT in the frontal cortex of freely moving rats. Br J Pharmacol 2005; 145: 587-592.
44. Huber TJ, Dietrich DE, Emrich HM. Possible use of amantadine in depression. Pharmacopsychiatry 1999; 32: 47-55.
45. Paul IA, Nowak G, Layer RT, Popik P, Skolnick P. Adaptation of the N-methyl-D-aspartate complex following chronic antidepressant treatment. J Pharmacol Exp Ther 1994; 269: 95-102.
46. 3 receptors in rats. J Physiol Pharmacol 2003; 54: 257-270.
47. 1-adrenergic system in rats. Behav Pharmacol 2004; 15: 159-165.
48. Porter RH, Greenamyre JT. Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J Neurochem 1995; 64: 614-623.
49. Zetterstrom TS, Pei Q, Madhav TR, Coppell AL, Lewis L, Grahame-Smith DG. Manipulations of brain 5-HT levels affect gene expression for BDNF in rat brain. Neuropharmacology 1999; 38: 1063-1073.
50. Smith MA, Zhang L, Lyons WE, Mamounas LA. Anterograde transport of endogenous brain-derived neurotrophic factor in hippocampal mossy fibers. Neuroreport 1997; 8: 1829-1834.
51. Altar CA, Whitehead RE, Chen R, Wortwein G, Madsen TM. Effect of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biol Psychiatry 2003; 54: 703-709.
52. Smith MA, Makino S, Kvetnansky R, Post MN. Stress alters the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 1995; 15: 1768-1777.
53. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of camp response element binding protein (CREB) in rat hippocampus. J Neurosci 1996; 16: 2365-2372.
54. 2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 1998; 20: 709-726.
55. Conti AC, Cryan JF, Dalvi A, Lucid I, Blendy JA. cAMP response element-binding protein is essential for the up-regulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci 2002; 22: 3262-3268.
56. Thome J, Sakai N, Shin K, et al. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci 2000; 20: 4030-4036.
57. Tiraboschi E, Tardito D, Kasahara J, et al. Selective phosphorylation of nuclear CREB by fluoxetine is linked to activation of CaM kinase IV and MAP kinase cascade. Neuropharmacology 2004; 29: 1831-1840.
58. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 1997; 56: 131-137.
59. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produced antidepressant effects in behavioural models of depression. J Neurosci 2002; 22: 3251-3261.
60. Hoshaw BA, Malberg JE, Lucki I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res 2005; 1037: 204-208.
61. Pencea V, Bingaman KD, Wiegand SJ, Luskin MB. Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus. J Neurosci 2001; 21: 6706-6717.
62. Kempermann G, Kronenberg G. Depressed new neurons - adult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression. Biol Psychiatry 2003; 54: 499-503.
63. Sheline YI, Wang PW, Gado MH, Csrrnansky JC, Vannier W. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 1996; 93: 3908-3913.
64. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry 200; 160: 1516-1518.
65. Duman RS. Depression: a case of neuronal life and death. Biol Psychiatry 2004; 56: 140-145.
66. Vermetten E, Vythilingam M, Southwick SM, Charney DS, Bremner JD. Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biol Psychiatry 2003; 54: 693-702.
67. Malberg JE, Blendy JA. Antidepressant action: to the nucleus and beyond. Trends Pharmacol Soc 2005; 26: 631-638.
68. Malberg JE, Schechter LB. Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drug. Curr Pharm Des 2005; 11: 145-155.